Labcorp Holdings Inc. $LH Stock Acquired by Everett Harris & Co. CA

Everett Harris & Co. CA raised its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 3.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 129,602 shares of the medical research company’s stock after purchasing an additional 4,913 shares during the period. Labcorp makes up approximately 0.5% of Everett Harris & Co. CA’s holdings, making the stock its 29th largest holding. Everett Harris & Co. CA owned approximately 0.16% of Labcorp worth $39,932,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in LH. Allied Private Wealth LLC bought a new position in shares of Labcorp during the 2nd quarter valued at about $33,000. Cedar Mountain Advisors LLC raised its holdings in shares of Labcorp by 786.7% during the 1st quarter. Cedar Mountain Advisors LLC now owns 133 shares of the medical research company’s stock valued at $35,000 after buying an additional 118 shares in the last quarter. William Mack & Associates Inc. bought a new stake in Labcorp in the 3rd quarter worth approximately $42,000. Jones Financial Companies Lllp bought a new stake in Labcorp in the 2nd quarter worth approximately $58,000. Finally, Ancora Advisors LLC purchased a new stake in Labcorp in the second quarter worth approximately $67,000. Institutional investors own 95.94% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Weiss Ratings upgraded shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, October 21st. Mizuho set a $355.00 price target on shares of Labcorp in a research note on Monday, August 10th. UBS Group boosted their price objective on shares of Labcorp from $380.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday. Leerink Partners set a $410.00 price objective on shares of Labcorp in a research note on Wednesday. Finally, Barclays raised their price objective on Labcorp from $330.00 to $380.00 and gave the company an “equal weight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $365.67.

Insider Buying and Selling

In other Labcorp news, EVP Amy B. Summy sold 924 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the sale, the executive vice president directly owned 6,956 shares in the company, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Adam H. Schechter sold 4,669 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the sale, the chief executive officer owned 102,565 shares in the company, valued at approximately $32,858,749.05. The trade was a 4.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,593 shares of company stock worth $2,733,295 in the last 90 days. Insiders own 0.84% of the company’s stock.

Labcorp Stock Up 2.0%

Shares of NYSE LH opened at $367.49 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.53 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 12 month low of $244.52 and a 12 month high of $371.00. The firm has a fifty day simple moving average of $322.64 and a two-hundred day simple moving average of $287.05. The firm has a market capitalization of $29.80 billion, a PE ratio of 19.91, a price-to-earnings-growth ratio of 2.05 and a beta of 0.87.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share for the quarter, beating the consensus estimate of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the firm posted $4.18 EPS. The business’s revenue was up 6.9% on a year-over-year basis. Equities analysts expect that Labcorp Holdings Inc. will post 18.36 earnings per share for the current year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s dividend payout ratio is 23.63%.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Third-quarter results exceeded expectations. Adjusted EPS was $4.78 versus the $4.64 analyst consensus, while revenue rose 6.9% year over year to $3.81 billion, ahead of the $3.76 billion forecast. Both Diagnostics Laboratories and Biopharma Laboratory Services delivered growth, with revenue increasing 6.5% and 8.5%, respectively. Labcorp Q3 2026 earnings highlights
• Positive Sentiment: Labcorp raised its 2026 guidance. The company now expects enterprise revenue growth of 5.9% to 6.7% and adjusted EPS of $18.30 to $18.70, supported by margin expansion, organic growth and recent transactions. It also announced or completed four deals and received FDA approval for a companion diagnostic used in advanced melanoma. Labcorp boosts FY26 outlook
• Positive Sentiment: Analysts raised their targets. Truist increased its target to $395 and maintained a Buy rating, while Robert W. Baird raised its target to $396 and kept an Outperform rating. Truist raises Labcorp price target
• Neutral Sentiment: Deutsche Bank raised its price target to $355 but retained a Hold rating, indicating limited upside at elevated trading levels. Deutsche Bank adjusts Labcorp price target
• Negative Sentiment: PAMA reimbursement risk remains an overhang. Investors are concerned that potential changes to laboratory payment rules could pressure future reimbursement and earnings. One analyst also downgraded the stock, arguing that optimism and valuation may have become excessive. Labcorp stock and PAMA risk

Labcorp Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.